Specialty
Cardiology devices
Last checked: Nov 19, 2026Source: openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
4,540
510(k), De Novo and PMA
Decisions, last 36 months
1,168
Recruiting device trials
498
Industry sponsored
Adverse event reports
123,005
Received Nov 1, 2025 to Nov 19, 2026
Narrower views
Latest FDA decisions
The 8 newest. A specialty is the FDA review panel, or a list of product codes for a narrower view.
K260436 · Decided Nov 6, 2026 · 268 days after receipt
Device type: Reduced Ejection Fraction Machine Learning-Based Notification Software (QYE) · Cardiology
K260608 · Decided Nov 6, 2026 · 255 days after receipt
Device type: Clamp, Vascular (DXC) · Cardiology
- Progreat Lambda 2.1Fr510(k)
Terumo Clinical Supply Co., Ltd.
K261376 · Decided Nov 5, 2026 · 192 days after receipt
Device type: Catheter, Continuous Flush (KRA) · Cardiology
- NeuroSheath510(k)
K261449 · Decided Nov 5, 2026 · 188 days after receipt
Device type: Catheter, Percutaneous, Neurovasculature (QJP) · Cardiology
- ANNE Limb510(k)
K261870 · Decided Nov 5, 2026 · 154 days after receipt
Device type: Oximeter (DQA) · Cardiology
K262171 · Decided Nov 5, 2026 · 132 days after receipt
Device type: Computer, Diagnostic, Programmable (DQK) · Cardiology
K262858 · Decided Nov 5, 2026 · 84 days after receipt
Device type: Oximeter, Tissue Saturation (MUD) · Cardiology
K263678 · Decided Nov 5, 2026 · 29 days after receipt
Device type: Filter, Intravascular, Cardiovascular (DTK) · Cardiology
FDA decisions per month
Last 36 months, by decision date and pathway.
- 510(k)
- De Novo
- PMA
View as table
| Month | 510(k) | De Novo | PMA |
|---|---|---|---|
| Dec 23 | 38 | 0 | 3 |
| Jan 24 | 18 | 0 | 3 |
| Feb 24 | 22 | 1 | 4 |
| Mar 24 | 28 | 0 | 0 |
| Apr 24 | 26 | 0 | 3 |
| May 24 | 31 | 0 | 1 |
| Jun 24 | 41 | 1 | 3 |
| Jul 24 | 26 | 0 | 0 |
| Aug 24 | 28 | 0 | 1 |
| Sep 24 | 26 | 1 | 0 |
| Oct 24 | 29 | 1 | 2 |
| Nov 24 | 31 | 0 | 2 |
| Dec 24 | 27 | 0 | 1 |
| Jan 25 | 27 | 0 | 1 |
| Feb 25 | 28 | 0 | 0 |
| Mar 25 | 23 | 0 | 0 |
| Apr 25 | 26 | 0 | 6 |
| May 25 | 35 | 1 | 3 |
| Jun 25 | 33 | 0 | 1 |
| Jul 25 | 32 | 0 | 3 |
| Aug 25 | 21 | 0 | 3 |
| Sep 25 | 33 | 0 | 0 |
| Oct 25 | 34 | 0 | 1 |
| Nov 25 | 22 | 0 | 0 |
| Dec 25 | 35 | 0 | 3 |
| Jan 26 | 35 | 0 | 2 |
| Feb 26 | 33 | 0 | 0 |
| Mar 26 | 27 | 0 | 3 |
| Apr 26 | 50 | 1 | 1 |
| May 26 | 28 | 1 | 0 |
| Jun 26 | 33 | 0 | 2 |
| Jul 26 | 42 | 1 | 2 |
| Aug 26 | 37 | 0 | 0 |
| Sep 26 | 39 | 2 | 3 |
| Oct 26 | 38 | 0 | 6 |
| Nov 26 | 12 | 0 | 1 |
Recruiting device trials
Industry-sponsored device trials that are recruiting now, most recently updated first.
- Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart FailurePivotal-lookingRecruiting
CVRx, Inc.Not on our public-company list
NCT07232030 · 2,500 participants (planned) · Start Apr 24, 2026 · Primary completion Jan 2033
Device: Barostim System · For: Heart Failure; Heart Failure NYHA Class II; Heart Failure NYHA Class III
Sites: Mobile, Alabama; Los Angeles, California; Clearwater, Florida · 26 sites in all
- Synchronized Diaphragmatic Stimulation in Symptomatic Heart FailurePivotal-lookingRecruiting
VisCardia Inc.Not on our public-company list
NCT06552637 · 270 participants (planned) · Start Jul 8, 2026 · Primary completion Jul 2028
Device: Synchronized Diaphragmatic Stimulation · For: Heart Failure With Reduced Ejection Fraction
Sites: Indianapolis, Indiana; Tulsa, Oklahoma; Philadelphia, Pennsylvania · 7 sites in all
Recross Cardio, Inc.Not on our public-company list
NCT07172464 · 30 participants (planned) · Start Oct 9, 2025 · Primary completion Aug 2027
Device: Recross P3 Occluder (P3O) System · For: PFO; PFO - Patent Foramen Ovale; Cryptogenic Stroke and 2 more
Sites: Los Angeles, California; Gainsville, Florida; Boston, Massachusetts · 4 sites in all
Recross Cardio, Inc.Not on our public-company list
NCT07698951 · 15 participants (planned) · Start Jun 17, 2026 · Primary completion Aug 2027
Device: Recross P3 Occluder (P3O) System · For: PFO; PFO - Patent Foramen Ovale; Cryptogenic Stroke and 2 more
Sites: Belgrade, Serbia; Kamenitz, Serbia
- Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)Pivotal-lookingRecruiting
Supira MedicalNot on our public-company list
NCT07296744 · 358 participants (planned) · Start May 11, 2026 · Primary completion Nov 2027
Device: The Supira System; Impella · For: Coronary Artery Disease; High Risk Percutaneous Coronary Intervention; Interventional Cardiology and 1 more
Sites: Loma Linda, California; Sacramento, California; Thousand Oaks, California · 27 sites in all
- The Neuralert Stroke Monitor Pilot TrialRecruiting
Neuralert Technologies LLCNot on our public-company list
NCT06368193 · 50 participants (planned) · Start Dec 12, 2024 · Primary completion Nov 14, 2027
Device: Neuralert Monitor · For: Stroke; Surgery
Sites: Philadelphia, Pennsylvania
How new technology gets paid for
Recent Medicare coverage decisions that touch this specialty.
Reports received
123,005
Received Nov 1, 2025 to Nov 19, 2026. Includes 451 of another or unstated type.
Malfunction reports
95,324
77% of reports
Injury reports
25,266
21% of reports
Death reports
1,964
1.6% of reports
Adverse event reports received per month
By the date FDA received each report. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Nov 25 | 6,690 | 1,967 | 121 | 1 |
| Dec 25 | 7,410 | 2,071 | 190 | 3 |
| Jan 26 | 7,848 | 2,032 | 197 | 1 |
| Feb 26 | 6,658 | 1,978 | 193 | 3 |
| Mar 26 | 7,878 | 2,402 | 195 | 2 |
| Apr 26 | 7,715 | 2,333 | 158 | 1 |
| May 26 | 7,249 | 2,191 | 168 | 1 |
| Jun 26 | 7,618 | 2,133 | 176 | 5 |
| Jul 26 | 8,401 | 2,127 | 153 | 14 |
| Aug 26 | 7,919 | 2,072 | 132 | 103 |
| Sep 26 | 12,236 | 2,055 | 146 | 119 |
| Oct 26 | 7,702 | 1,905 | 135 | 198 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types with the most reports
Widely used device types get more reports. This is not a ranking of safety.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.